0000000000547683

AUTHOR

M. Asunción Aguilar

showing 2 related works from this author

Antagonism of corticotropin-releasing factor CRF 1 receptors blocks the enhanced response to cocaine after social stress

2018

Numerous studies have shown that social defeat stress induces an increase in the rewarding effects of cocaine. In this study we have investigated the role played by the main hypothalamic stress hormone, corticotropin-releasing factor (CRF), in the effects that repeated social defeat (RSD) induces in the conditioned rewarding effects and locomotor sensitization induced by cocaine. A total of 220 OF1 mice were divided into experimental groups according to the treatment received before each social defeat: saline, 5 or 10 mg/kg of the nonpeptidic corticotropin-releasing factor CRF1 receptor antagonist CP-154,526, or 15 or 30 µg/kg of the peptidic corticotropin-releasing factor CRF2 receptor ant…

PharmacologySocial stressbusiness.industrymedicine.drug_classAntagonistPharmacologyReceptor antagonistConditioned place preference030227 psychiatryCorticotropin-releasing hormone receptor 1Social defeat03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureAnxiogenicmedicinebusiness030217 neurology & neurosurgerySensitizationEuropean Journal of Pharmacology
researchProduct

Lack of Specific Effects of Selective D1 and D2 Dopamine Antagonists vs. Risperidone on Morphine-Induced Hyperactivity

2000

Abstract RODRIGUEZ-ARIAS, M., I. BROSETA, M. A. AGUILAR AND J. MINARRO. Lack of specific effects of selective D 1 and D 2 dopamine antagonists on morphine-induced hyperactivity. PHARMACOL BIOCHEM BEHAV 66 (1) 189–197, 2000.—In the present study, three different dopamine antagonists were challenged in order to counteract hyperactivity induced by 50 mg/kg of morphine. A wide range of doses of morphine (50, 25, 12.5, 6.25, or 3.12 mg/kg) were evaluated on spontaneous locomotor activity. A significant increase was observed only with the two higher doses tested (25 and 50 mg/kg). No decrease was found with any of the doses used at any period of time. After analyzing doses of SCH 23390 (0.5, 0.1,…

MaleNarcoticsmedicine.medical_specialtyClinical BiochemistryMotor ActivityPharmacologyCatalepsyToxicologyBiochemistryMiceBehavioral Neurosciencechemistry.chemical_compoundDopamineInternal medicinemedicineAnimalsBiological PsychiatryPharmacologyRacloprideCatalepsySCH-23390RisperidoneMorphineChemistryReceptors Dopamine D1AntagonistDopamine antagonistBenzazepinesRisperidonemedicine.diseaseDopamine D2 Receptor AntagonistsEndocrinologyRacloprideMorphineDopamine Antagonistsmedicine.drugPharmacology Biochemistry and Behavior
researchProduct